Evidence map›Paper›PMID 41543663›Full record

ArticleInsights into imaging2026

The role of multimodality imaging in selection, response assessment, and follow-up of patients receiving

Aditi Ranjan, Minal Padden-Modi, Hoda Abdel-Aty, Joao Galante, Simon Wan, Azzra Maricar, Adetokunbo Adesina, Brent Drake, Siraj Yusuf, Gary Cook and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Insights into imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Aditi Ranjan *Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Minal Padden-Modi *Institute of Cancer Research and Royal Marsden Hospital NHS Foundation Trust, London, UK.
Hoda Abdel-AtyInstitute of Cancer Research and Royal Marsden Hospital NHS Foundation Trust, London, UK.
Joao GalanteOncology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Simon WanInstitute of Nuclear Medicine, University College London Hospitals NHS Foundation Trust, London, UK.
Azzra MaricarKing's College London, London, UK.
Adetokunbo AdesinaBuckinghamshire Hospitals NHS Trust, Amersham, UK.
Brent DrakeRadiology and Nuclear Medicine Department, Royal Marsden NHS Foundation Trust, London, UK.
Siraj YusufRadiology and Nuclear Medicine Department, Royal Marsden NHS Foundation Trust, London, UK.
Gary CookKing's College London, Cancer Imaging PET Centre, St Thomas' Hospital, London, UK.
Nicholas JamesInstitute of Cancer Research and Royal Marsden Hospital NHS Foundation Trust, London, UK.
Sola AdelekeKCL, School of Biomedical Engineering and Imaging Sciences, Becket House, London, UK. Olusola.adeleke@kcl.ac.uk.ORCID http://orcid.org/0009-0004-9781-973X

Funding

No funding
6 · The paper itself

Abstract

Prostate cancer is the most commonly diagnosed cancer among men in 112 countries, accounting for approximately 15% of all cancer cases. Whilst the 5-year survival rate for localised disease exceeds 90%, there is a significant drop to 50% if metastases are present. Following the VISION and TheraP trials,

Indexed as

Molecular imaging–cancerMRI-diffusion-weighted imagingProstatePSMA-PET/CT

Identifiers

PMID41543663
PMCPMC12811189

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.